Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation
2016年12月1日 更新者:GlaxoSmithKline
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation
The purpose of this study is to evaluate efficacy and safety of Omacor (omega-3-acid ethyl esters) in patients with recurrent, symptomatic atrial fibrillation.
調査の概要
研究の種類
介入
入学 (実際)
663
段階
- フェーズ 3
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35215
- GSK Investigational Site
-
Huntsville、Alabama、アメリカ、35801
- GSK Investigational Site
-
-
Alaska
-
Anchorage、Alaska、アメリカ、99508
- GSK Investigational Site
-
-
Arizona
-
Cottonwood、Arizona、アメリカ、86326
- GSK Investigational Site
-
Mesa、Arizona、アメリカ、85206
- GSK Investigational Site
-
Phoenix、Arizona、アメリカ、85006
- GSK Investigational Site
-
Phoenix、Arizona、アメリカ、85032
- GSK Investigational Site
-
Phoenix、Arizona、アメリカ、85014
- GSK Investigational Site
-
Tucson、Arizona、アメリカ、85724
- GSK Investigational Site
-
-
Arkansas
-
Fort Smith、Arkansas、アメリカ、72901
- GSK Investigational Site
-
Hot Springs、Arkansas、アメリカ、71913
- GSK Investigational Site
-
-
California
-
Alamada、California、アメリカ、94501
- GSK Investigational Site
-
Bakersfield、California、アメリカ、93301
- GSK Investigational Site
-
Bakersfield、California、アメリカ、93308
- GSK Investigational Site
-
Beverly Hills、California、アメリカ、90210
- GSK Investigational Site
-
Carmichael、California、アメリカ、95608
- GSK Investigational Site
-
Fair Oaks、California、アメリカ、95628
- GSK Investigational Site
-
Fountain Valley、California、アメリカ、92708
- GSK Investigational Site
-
Loma Linda、California、アメリカ、92354
- GSK Investigational Site
-
Los Angeles、California、アメリカ、90073
- GSK Investigational Site
-
Los Angeles、California、アメリカ、90048
- GSK Investigational Site
-
Los Angeles、California、アメリカ、90033
- GSK Investigational Site
-
Los Angeles、California、アメリカ、90211
- GSK Investigational Site
-
Merced、California、アメリカ、95348
- GSK Investigational Site
-
Palm Springs、California、アメリカ、92262
- GSK Investigational Site
-
Poway、California、アメリカ、92064
- GSK Investigational Site
-
Redondo Beach、California、アメリカ、90277
- GSK Investigational Site
-
Sacramento、California、アメリカ、95819
- GSK Investigational Site
-
San Diego、California、アメリカ、92123
- GSK Investigational Site
-
San Diego、California、アメリカ、92120
- GSK Investigational Site
-
San Diego、California、アメリカ、92161
- GSK Investigational Site
-
Vista、California、アメリカ、92081
- GSK Investigational Site
-
Walnut Creek、California、アメリカ、94598
- GSK Investigational Site
-
-
Colorado
-
Aurora、Colorado、アメリカ、80012
- GSK Investigational Site
-
Colorado Springs、Colorado、アメリカ、80907
- GSK Investigational Site
-
Littleton、Colorado、アメリカ、80120
- GSK Investigational Site
-
-
Connecticut
-
Bridgeport、Connecticut、アメリカ、06606
- GSK Investigational Site
-
Farmington、Connecticut、アメリカ、06030
- GSK Investigational Site
-
Guilford、Connecticut、アメリカ、06437
- GSK Investigational Site
-
-
District of Columbia
-
Washington、District of Columbia、アメリカ、20010
- GSK Investigational Site
-
Washington、District of Columbia、アメリカ、20017
- GSK Investigational Site
-
-
Florida
-
Aventura、Florida、アメリカ、33180
- GSK Investigational Site
-
Bay Pines、Florida、アメリカ、33744
- GSK Investigational Site
-
Daytona Beach、Florida、アメリカ、32114
- GSK Investigational Site
-
Delray Beach、Florida、アメリカ、33484
- GSK Investigational Site
-
Fort Meyers、Florida、アメリカ、33919
- GSK Investigational Site
-
Gainesville、Florida、アメリカ、32605
- GSK Investigational Site
-
Hudson、Florida、アメリカ、34667
- GSK Investigational Site
-
Jacksonville、Florida、アメリカ、32216
- GSK Investigational Site
-
Jacksonville、Florida、アメリカ、32207
- GSK Investigational Site
-
Jupiter、Florida、アメリカ、33458
- GSK Investigational Site
-
Kissimmee、Florida、アメリカ、34741
- GSK Investigational Site
-
Largo、Florida、アメリカ、33773
- GSK Investigational Site
-
Melbourne、Florida、アメリカ、32901
- GSK Investigational Site
-
Miami、Florida、アメリカ、33136
- GSK Investigational Site
-
Miami、Florida、アメリカ、33137
- GSK Investigational Site
-
Miami、Florida、アメリカ、33176
- GSK Investigational Site
-
Ocala、Florida、アメリカ、34471
- GSK Investigational Site
-
Orlando、Florida、アメリカ、32803
- GSK Investigational Site
-
Ormond Beach、Florida、アメリカ、32174
- GSK Investigational Site
-
Pensacola、Florida、アメリカ、32514
- GSK Investigational Site
-
Pinellas Park、Florida、アメリカ、33781
- GSK Investigational Site
-
Tampa、Florida、アメリカ、33607
- GSK Investigational Site
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30342
- GSK Investigational Site
-
Atlanta、Georgia、アメリカ、30322
- GSK Investigational Site
-
Atlanta、Georgia、アメリカ、30328
- GSK Investigational Site
-
Decatur、Georgia、アメリカ、30030
- GSK Investigational Site
-
Tucker、Georgia、アメリカ、30084
- GSK Investigational Site
-
-
Illinois
-
Bannockburn、Illinois、アメリカ、60015
- GSK Investigational Site
-
Gurnee、Illinois、アメリカ、60031
- GSK Investigational Site
-
Normal、Illinois、アメリカ、61761
- GSK Investigational Site
-
Peoria、Illinois、アメリカ、61603
- GSK Investigational Site
-
-
Indiana
-
Elkhart、Indiana、アメリカ、46514
- GSK Investigational Site
-
Indianapolis、Indiana、アメリカ、46260
- GSK Investigational Site
-
La Porte、Indiana、アメリカ、46350
- GSK Investigational Site
-
South Bend、Indiana、アメリカ、46601
- GSK Investigational Site
-
-
Kansas
-
Kansas City、Kansas、アメリカ、66102
- GSK Investigational Site
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40205
- GSK Investigational Site
-
Mount Sterling、Kentucky、アメリカ、40353
- GSK Investigational Site
-
-
Louisiana
-
Covington、Louisiana、アメリカ、70433
- GSK Investigational Site
-
Lacombe、Louisiana、アメリカ、70445
- GSK Investigational Site
-
-
Maine
-
Auburn、Maine、アメリカ、04210
- GSK Investigational Site
-
Biddeford、Maine、アメリカ、04005
- GSK Investigational Site
-
Portland、Maine、アメリカ、04106
- GSK Investigational Site
-
Scarborough、Maine、アメリカ、04074
- GSK Investigational Site
-
-
Maryland
-
Annapolis、Maryland、アメリカ、20401
- GSK Investigational Site
-
-
Massachusetts
-
Ayer、Massachusetts、アメリカ、01432
- GSK Investigational Site
-
Brookline、Massachusetts、アメリカ、02446
- GSK Investigational Site
-
Worcester、Massachusetts、アメリカ、01655
- GSK Investigational Site
-
-
Michigan
-
Alpena、Michigan、アメリカ、49707
- GSK Investigational Site
-
Cadillac、Michigan、アメリカ、49601
- GSK Investigational Site
-
Detroit、Michigan、アメリカ、48201
- GSK Investigational Site
-
Kalamazoo、Michigan、アメリカ、49048
- GSK Investigational Site
-
Lansing、Michigan、アメリカ、48910
- GSK Investigational Site
-
-
Minnesota
-
Mineappolis、Minnesota、アメリカ、55417
- GSK Investigational Site
-
Rochester Hills、Minnesota、アメリカ、48307
- GSK Investigational Site
-
St Paul、Minnesota、アメリカ、55102
- GSK Investigational Site
-
-
Mississippi
-
Gulfport、Mississippi、アメリカ、39503
- GSK Investigational Site
-
-
Montana
-
Billings、Montana、アメリカ、59101
- GSK Investigational Site
-
Kalispell、Montana、アメリカ、59901
- GSK Investigational Site
-
Missoula、Montana、アメリカ、59802
- GSK Investigational Site
-
-
New Jersey
-
Morristown、New Jersey、アメリカ、07962
- GSK Investigational Site
-
Summit、New Jersey、アメリカ、07901
- GSK Investigational Site
-
Wayne、New Jersey、アメリカ、07470
- GSK Investigational Site
-
-
New York
-
Babylon、New York、アメリカ、11702
- GSK Investigational Site
-
Buffalo、New York、アメリカ、14215
- GSK Investigational Site
-
Buffalo、New York、アメリカ、14209
- GSK Investigational Site
-
Mineola、New York、アメリカ、11501
- GSK Investigational Site
-
New York、New York、アメリカ、10032
- GSK Investigational Site
-
New York、New York、アメリカ、10025
- GSK Investigational Site
-
New York、New York、アメリカ、10021
- GSK Investigational Site
-
New York、New York、アメリカ、10029
- GSK Investigational Site
-
Troy、New York、アメリカ、12180
- GSK Investigational Site
-
West Islip、New York、アメリカ、11794
- GSK Investigational Site
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28203
- GSK Investigational Site
-
Charlotte、North Carolina、アメリカ、28080
- GSK Investigational Site
-
Hickory、North Carolina、アメリカ、28601
- GSK Investigational Site
-
Statesville、North Carolina、アメリカ、28625
- GSK Investigational Site
-
-
North Dakota
-
Grand Forks、North Dakota、アメリカ、58201
- GSK Investigational Site
-
-
Ohio
-
Akron、Ohio、アメリカ、44304
- GSK Investigational Site
-
Bryan、Ohio、アメリカ、43506
- GSK Investigational Site
-
Cincinnati、Ohio、アメリカ、45219
- GSK Investigational Site
-
Cleveland、Ohio、アメリカ、44106
- GSK Investigational Site
-
Fairview Park、Ohio、アメリカ、44126
- GSK Investigational Site
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73103
- GSK Investigational Site
-
Oklahoma City、Oklahoma、アメリカ、73104
- GSK Investigational Site
-
Oklahoma City、Oklahoma、アメリカ、73109
- GSK Investigational Site
-
-
Oregon
-
Corvalis、Oregon、アメリカ、97330
- GSK Investigational Site
-
Hillsboro、Oregon、アメリカ、97123-4117
- GSK Investigational Site
-
Portland、Oregon、アメリカ、97220
- GSK Investigational Site
-
Portland、Oregon、アメリカ、97223
- GSK Investigational Site
-
-
Pennsylvania
-
Beaver、Pennsylvania、アメリカ、15009
- GSK Investigational Site
-
Greensburg、Pennsylvania、アメリカ、15601
- GSK Investigational Site
-
Hershey、Pennsylvania、アメリカ、17033
- GSK Investigational Site
-
Langhorne、Pennsylvania、アメリカ、19047
- GSK Investigational Site
-
Philadelphia、Pennsylvania、アメリカ、19102
- GSK Investigational Site
-
Ridley Park、Pennsylvania、アメリカ、19078
- GSK Investigational Site
-
West Chester、Pennsylvania、アメリカ、19380
- GSK Investigational Site
-
Wynnewood、Pennsylvania、アメリカ、19096
- GSK Investigational Site
-
Wyomissing、Pennsylvania、アメリカ、19610
- GSK Investigational Site
-
-
Rhode Island
-
Cranston、Rhode Island、アメリカ、02920
- GSK Investigational Site
-
Pawtucket、Rhode Island、アメリカ、02860
- GSK Investigational Site
-
Westerly、Rhode Island、アメリカ、02891
- GSK Investigational Site
-
-
South Carolina
-
Greer、South Carolina、アメリカ、29651
- GSK Investigational Site
-
Spartanburg、South Carolina、アメリカ、29302
- GSK Investigational Site
-
-
South Dakota
-
Sioux Falls、South Dakota、アメリカ、57105
- GSK Investigational Site
-
-
Tennessee
-
Jackson、Tennessee、アメリカ、38301
- GSK Investigational Site
-
Memphis、Tennessee、アメリカ、38120
- GSK Investigational Site
-
-
Texas
-
Austin、Texas、アメリカ、78705
- GSK Investigational Site
-
Beaumont、Texas、アメリカ、77702
- GSK Investigational Site
-
Corpus Christi、Texas、アメリカ、78404
- GSK Investigational Site
-
Dallas、Texas、アメリカ、75230
- GSK Investigational Site
-
Dallas、Texas、アメリカ、75231
- GSK Investigational Site
-
Houston、Texas、アメリカ、77074
- GSK Investigational Site
-
Houston、Texas、アメリカ、77090
- GSK Investigational Site
-
Humble、Texas、アメリカ、77338
- GSK Investigational Site
-
Lubbock、Texas、アメリカ、79410
- GSK Investigational Site
-
McKinney、Texas、アメリカ、75069
- GSK Investigational Site
-
Odessa、Texas、アメリカ、79761
- GSK Investigational Site
-
Odessa、Texas、アメリカ、79764
- GSK Investigational Site
-
Orange、Texas、アメリカ、77630
- GSK Investigational Site
-
Tyler、Texas、アメリカ、75701
- GSK Investigational Site
-
Waco、Texas、アメリカ、76712
- GSK Investigational Site
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84124
- GSK Investigational Site
-
-
Virginia
-
Arlington、Virginia、アメリカ、22204
- GSK Investigational Site
-
Chesapeake、Virginia、アメリカ、23510
- GSK Investigational Site
-
Galax、Virginia、アメリカ、24333
- GSK Investigational Site
-
Richlands、Virginia、アメリカ、24641
- GSK Investigational Site
-
Richmond、Virginia、アメリカ、23249
- GSK Investigational Site
-
Richmond、Virginia、アメリカ、23294
- GSK Investigational Site
-
Springfield、Virginia、アメリカ、22151
- GSK Investigational Site
-
-
Washington
-
Burien、Washington、アメリカ、98166
- GSK Investigational Site
-
-
West Virginia
-
Huntington、West Virginia、アメリカ、25701
- GSK Investigational Site
-
-
Wisconsin
-
Beloit、Wisconsin、アメリカ、53511
- GSK Investigational Site
-
Madison、Wisconsin、アメリカ、53792
- GSK Investigational Site
-
Marshfield、Wisconsin、アメリカ、54449
- GSK Investigational Site
-
Milwaukee、Wisconsin、アメリカ、53215
- GSK Investigational Site
-
Wausau、Wisconsin、アメリカ、54401
- GSK Investigational Site
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
18年歳以上 (大人、高齢者)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
全て
説明
Inclusion Criteria:
- Men and women age 18 years or older
- History of symptomatic atrial fibrillation (either paroxysmal or persistent)
- Provide written informed consent and authorization for protected health information disclosure
Exclusion Criteria:
- Permanent (chronic) atrial fibrillation
- Antiarrhythmic drug therapy which cannot be stopped
- Use of amiodarone with prior 6 months
- History of unsuccessful cardioversion
- History of certain cardiovascular conditions or cardiac surgery within prior 6 months
- History of stroke within prior 6 months
- Implanted cardio-defibrillator
- Certain circulatory, thyroid, pulmonary, liver, kidney, musculoskeletal or metabolic conditions, or cancer (except non-melanoma skin cancer)
- Poorly controlled diabetes
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:プラセボ
|
|
|
実験的:omega-3-acid ethyl esters
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Paroxysmal AF With an Event of Documented Symptomatic Atrial Fibrillation (AF)/Flutter
時間枠:From first dose of study drug (Day 1) to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
A documented episode of symptomatic AF /Flutter was defined as AF/Flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals.
The occurrence of symptomatic atrial flutter was treated as an occurrence of symptomatic AF for this outcome measure.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF or flutter.
|
From first dose of study drug (Day 1) to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Persistent AF and in Both AF Subgroups Combined With an Event of Documented Symptomatic AF/Flutter
時間枠:From first dose of study drug (Day 1) to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
A documented episode of symptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals.
The occurrence of symptomatic atrial flutter was treated as an occurrence of symptomatic AF for this outcome measure.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF or flutter.
|
From first dose of study drug (Day 1) to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
|
Number of Participants With Paroxysmal AF or Persistent AF With an Event of Documented Symptomatic AF (Exclusive of Atrial Flutter)
時間枠:From first dose of study drug (Day 1) to the first symptomatic recurrence of AF (up to Week 24)
|
A documented episode of symptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF.
|
From first dose of study drug (Day 1) to the first symptomatic recurrence of AF (up to Week 24)
|
|
Number of Participants in Both AF Subgroups Combined With an Event of Documented Symptomatic AF (Exclusive of Atrial Flutter)
時間枠:From first dose of study drug (Day 1) to the first symptomatic recurrence of AF (up to Week 24)
|
A documented episode of symptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF.
|
From first dose of study drug (Day 1) to the first symptomatic recurrence of AF (up to Week 24)
|
|
Number Participants With Paroxysmal or Persistent AF With an Event of Documented Symptomatic or Asymptomatic AF/Flutter
時間枠:From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF/flutter (up to Week 24)
|
A documented episode of symptomatic or asymptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Asymptomatic episodes of AF or flutter were recorded by TTM during routine bi-weekly transmissions.
Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic or asymptomatic AF/flutter.
|
From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF/flutter (up to Week 24)
|
|
Number of Participants in Both AF Subgroups Combined With an Event of Documented Symptomatic or Asymptomatic AF/Flutter
時間枠:From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF/flutter (up to Week 24)
|
A documented episode of symptomatic or asymptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Asymptomatic episodes of AF or flutter were recorded by TTM during routine bi-weekly transmissions.
Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic or asymptomatic AF/flutter.
|
From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF/flutter (up to Week 24)
|
|
Number of Participants With Paroxysmal or Persistent AF With an Event of Documented Symptomatic or Asymptomatic AF (Exclusive of Flutter)
時間枠:From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF (up to Week 24)
|
A documented episode of symptomatic or asymptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Asymptomatic episodes of AF were recorded by TTM during routine bi-weekly transmissions.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic or asymptomatic AF/flutter.
|
From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF (up to Week 24)
|
|
Number of Participants in Both AF Subgroups Combined With an Event of Documented Symptomatic or Asymptomatic AF (Exclusive of Flutter)
時間枠:From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF (up to Week 24)
|
A documented episode of symptomatic or asymptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Asymptomatic episodes of AF were recorded by TTM during routine bi-weekly transmissions.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic or asymptomatic AF/flutter.
|
From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF (up to Week 24)
|
|
Number of Participants With Paroxysmal or Persistent AF With an Event After Completion of Day 7 to the Occurrence of Symptomatic AF/Flutter
時間枠:From completion of Day 7 of study drug to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
A documented episode of symptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF/flutter.
|
From completion of Day 7 of study drug to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
|
Number of Participants in the Combined AF Subgroups With an Event After Completion of Day 7 to the Occurrence of Symptomatic AF/Flutter
時間枠:From completion of Day 7 of study drug to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
A documented episode of symptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF/flutter.
|
From completion of Day 7 of study drug to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
|
Number of Participants With Paroxysmal or Persistent AF With an Event That Occurred After Completion of Day 7 to the Occurrence of Symptomatic AF (Exclusive of Flutter)
時間枠:From completion of Day 7 of study drug to the first symptomatic recurrence of AF (up to Week 24)
|
A documented episode of symptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF.
|
From completion of Day 7 of study drug to the first symptomatic recurrence of AF (up to Week 24)
|
|
Number of Participants in the Combined AF Subgroups With an Event That Occurred After Completion of Day 7 to the Occurrence of Symptomatic AF (Exclusive of Flutter)
時間枠:From completion of Day 7 of study drug to the first symptomatic recurrence of AF (up to Week 24)
|
A documented episode of symptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF.
|
From completion of Day 7 of study drug to the first symptomatic recurrence of AF (up to Week 24)
|
|
Annualized Number of AF/Flutter Rescue Episodes During the Treatment Period
時間枠:From first dose of study drug (Day 1) to the last dose of study drug (up to Week 24)
|
Rescue was defined as any pharmacological/electrical/surgical intervention for the termination/prevention of AF/flutter with a maximum of one rescue episode counted per day.
Note: all annualized values were calculated by counting the number of rescue episodes, dividing by the number of days on treatment, then multiplying that number by 365.25.
|
From first dose of study drug (Day 1) to the last dose of study drug (up to Week 24)
|
|
Annualized Cumulative Frequency of Symptomatic AF/Flutter Recurrences During the Treatment Period
時間枠:From first dose of study drug (Day 1) to the last dose of study drug (up to Week 24)
|
Values were annualized by counting the number of episodes of symptomatic AF/flutter recurrences (maximum of one per day), dividing by the number of days on treatment, then multiplying this number by 365.25.
|
From first dose of study drug (Day 1) to the last dose of study drug (up to Week 24)
|
|
Annualized Cumulative Frequency of Symptomatic AF Recurrences During the Treatment Period
時間枠:From first dose of study drug (Day 1) to the last dose of study drug (up to Week 24)
|
Values were annualized by counting the number of episodes of symptomatic AF recurrences (maximum of one per day), dividing by the number of days on treatment, then multiplying this number by 365.25.
|
From first dose of study drug (Day 1) to the last dose of study drug (up to Week 24)
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
出版物と役立つリンク
研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。
一般刊行物
- Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA. 2010 Dec 1;304(21):2363-72. doi: 10.1001/jama.2010.1735. Epub 2010 Nov 15.
- Pratt CM, Reiffel JA, Ellenbogen KA, Naccarelli GV, Kowey PR. Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study. Am Heart J. 2009 Aug;158(2):163-169.e1-3. doi: 10.1016/j.ahj.2009.05.024.
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始
2006年11月1日
一次修了 (実際)
2010年1月1日
研究の完了 (実際)
2010年1月1日
試験登録日
最初に提出
2006年11月20日
QC基準を満たした最初の提出物
2006年11月20日
最初の投稿 (見積もり)
2006年11月22日
学習記録の更新
投稿された最後の更新 (見積もり)
2017年1月30日
QC基準を満たした最後の更新が送信されました
2016年12月1日
最終確認日
2016年12月1日
詳しくは
本研究に関する用語
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
はい
IPD プランの説明
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
試験データ・資料
-
インフォームド コンセント フォーム
情報識別子:OM8 Afib情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
-
個人参加者データセット
情報識別子:OM8 Afib情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
-
注釈付き症例報告書
情報識別子:OM8 Afib情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
-
データセット仕様
情報識別子:OM8 Afib情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
-
研究プロトコル
情報識別子:OM8 Afib情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
-
統計分析計画
情報識別子:OM8 Afib情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
-
臨床研究報告書
情報識別子:OM8 Afib情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。